Emcure to maintain its growth pace in FY21 by expanding its product line

Emcure Pharmaceuticals, one of the quickest growing medication producers in the domestic market in terms of sales, intends to expand its product range through new releases, line expansions of current brands, and a concentration on digital sales.

The privately held Pune-based business intends to initially bring generic medicines to market through its own R&D activities, followed by novel compounds via in-licensing agreements.

In an interview with Moneycontrol, Namita Thapar, Executive Director, Emcure, who handles the India business, stated that despite COVID-related interruptions, the firm was able to expand above the market in FY21. During normal times, the Indian market rises by about 10%.

Thapar anticipates that the growth trend would continue in FY22. Emcure is placed 12th in FY21, according to All Indian Origin Chemists and Dealers (AIOCD) statistics, with an average sales growth of 8.5 percent. During the same time period, the Indian pharmaceutical market rose by 2.1 percent. AIOCD is a pharmaceutical market research firm that analyses brand and business sales.

Emcure does not release sales numbers because it is a privately held firm. According to credit rating agency CRISIL, the firm made Rs 5,082 crore in revenue in FY20. India accounted for about half of all sales. Emcure’s India sales are made up of chronic and sub-chronic categories such as gynaecological, cardiac, diabetes, cancer, vitamins, and anti-infectives.

NEWS SOURCE

ALSO READ : Wipro has announced a salary increase for 80%of its eligible employees